Literature DB >> 32551099

Proposal for a EN 149 acceptable reprocessing method for FFP2 respirators in times of severe shortage.

Andreas F Widmer1, Gilles Richner2.   

Abstract

Introduction: Transmission of SARS-CoV-2 to health care workers (HCW) poses a major burden in the current COVID-19 pandemic. Unprotected exposure to a COVID-19 patient is a key risk factor for HCWs. Transmission mainly occurs by droplet transmission, or by aerosol generating procedures. Respirators such as filtering face piece masks (FFP2), also called respirators, are required to prevent transmission during aerosol generating procedures, as part of the personal protective equipment (PPE) for HCWs. However, many HCW were infected due to lack of PPE, or failure to use them. Therefore, the worldwide shortage of respirators triggered the development of reprocessing used FFP2 respirators or N95 respirators as standard in the US. Our proposal with H2O2 plasma sterilization for decontamination allows to reprocess FFP2, while they still meet the filtration efficiency required by EN 149. The protocol is simple, uses available resources in hospitals and can be rapidly implemented to decrease the shortage of respirators during this crisis. The goal of the study was the evaluate if respirators can be reprocessed and still fulfill the requirements for filtration efficiency outlined by EN 149.
Methods: Used FFP2 respirators - Model 3 M Aura™ 1862+ - were sterilized using a low temperature process hydrogen peroxide (H2O2), V-PRO® maX Low Temperature, a FDA (Food and Drug Administration) approved method to decontaminate FFP2 respirators. Decontaminated respirators were further checked for residual peroxide by a single-gas detector for H2O2. The total inward leakage of the protective respirators was quantitatively tested with 10 test persons in an atmosphere charged with paraffin aerosol according to the European Standard EN 149. The fit factor was calculated as the inverse of the total inward leakage.
Results: Ten new and ten decontaminated FFP2 respirators were tested for filtration efficiency. None of the respirators exceeded the maximum acceptable concentration of peroxide. More than 4000 respirators have been reprocessed so far, at cost of approximately 0.3 Euro/piece. Conclusions: FFP2 respirators can be safely reprocessed once after decontamination with plasma peroxide sterilization, whereafter they still fulfill EN 149 requirements. This allows to almost double the current number of available FFP2 respirators.
© The Author(s) 2020.

Keywords:  FFP2; Infection control; Personal protection equipment; Reprocessing; Respirators; Sterilization

Mesh:

Substances:

Year:  2020        PMID: 32551099      PMCID: PMC7298450          DOI: 10.1186/s13756-020-00744-3

Source DB:  PubMed          Journal:  Antimicrob Resist Infect Control        ISSN: 2047-2994            Impact factor:   4.887


  13 in total

1.  Comparison of low-temperature hydrogen peroxide gas plasma sterilization for endoscopes using various Sterrad models.

Authors:  J Okpara-Hofmann; M Knoll; M Dürr; B Schmitt; M Borneff-Lipp
Journal:  J Hosp Infect       Date:  2005-04       Impact factor: 3.926

2.  Assessment of influenza virus exposure and recovery from contaminated surgical masks and N95 respirators.

Authors:  Francoise M Blachere; William G Lindsley; Cynthia M McMillen; Donald H Beezhold; Edward M Fisher; Ronald E Shaffer; John D Noti
Journal:  J Virol Methods       Date:  2018-07-17       Impact factor: 2.014

3.  Persistence of the 2009 pandemic influenza A (H1N1) virus on N95 respirators.

Authors:  A D Coulliette; K A Perry; J R Edwards; J A Noble-Wang
Journal:  Appl Environ Microbiol       Date:  2013-01-18       Impact factor: 4.792

4.  N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel: A Randomized Clinical Trial.

Authors:  Lewis J Radonovich; Michael S Simberkoff; Mary T Bessesen; Alexandria C Brown; Derek A T Cummings; Charlotte A Gaydos; Jenna G Los; Amanda E Krosche; Cynthia L Gibert; Geoffrey J Gorse; Ann-Christine Nyquist; Nicholas G Reich; Maria C Rodriguez-Barradas; Connie Savor Price; Trish M Perl
Journal:  JAMA       Date:  2019-09-03       Impact factor: 56.272

5.  COVID-19: protecting health-care workers.

Authors: 
Journal:  Lancet       Date:  2020-03-21       Impact factor: 79.321

6.  Can N95 Respirators Be Reused after Disinfection? How Many Times?

Authors:  Lei Liao; Wang Xiao; Mervin Zhao; Xuanze Yu; Haotian Wang; Qiqi Wang; Steven Chu; Yi Cui
Journal:  ACS Nano       Date:  2020-05-05       Impact factor: 15.881

7.  Evaluation of five decontamination methods for filtering facepiece respirators.

Authors:  Dennis J Viscusi; Michael S Bergman; Benjamin C Eimer; Ronald E Shaffer
Journal:  Ann Occup Hyg       Date:  2009-10-04

Review 8.  WHO International Health Regulations Emergency Committee for the COVID-19 outbreak.

Authors:  Youngmee Jee
Journal:  Epidemiol Health       Date:  2020-03-19

9.  Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020.

Authors:  Anne Kimball; Kelly M Hatfield; Melissa Arons; Allison James; Joanne Taylor; Kevin Spicer; Ana C Bardossy; Lisa P Oakley; Sukarma Tanwar; Zeshan Chisty; Jeneita M Bell; Mark Methner; Josh Harney; Jesica R Jacobs; Christina M Carlson; Heather P McLaughlin; Nimalie Stone; Shauna Clark; Claire Brostrom-Smith; Libby C Page; Meagan Kay; James Lewis; Denny Russell; Brian Hiatt; Jessica Gant; Jeffrey S Duchin; Thomas A Clark; Margaret A Honein; Sujan C Reddy; John A Jernigan
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-04-03       Impact factor: 17.586

10.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.